Navigation Links
Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
Date:7/28/2010

pectively, compared to an absolute improvement of 0.9 percentage points in the registry group. Among these patients (i.e., LVEFs less than or equal to 45), those in both the medium and high dose groups exhibited a substantial increases in LVEF, representing more than 25% improvements relative to baseline LVEF for those patient groups. Additional analysis of the echocardiogram data is ongoing, and we will evaluate possible effects on other measures of heart function.

"These preliminary phase I MultiStem results are consistent with the results obtained in preclinical studies and compare favorably to the results from other cell therapy treatments for AMI. This suggests that MultiStem could have a meaningful impact on improving heart function following heart attack," stated Dr. Warren Sherman, co-principal investigator and Director of Stem Cell Research and Regenerative Medicine, Center for Interventional Vascular Therapy at Columbia University Medical Center in New York.

Further Evaluation and Development

Athersys and Angiotech will continue to evaluate the phase I results and intend to begin planning for a subsequent clinical study, which they currently anticipate will be initiated in 2011. Further guidance about subsequent clinical development, such as trial design and timing, will be provided after evaluation and planning are completed and discussion with the FDA has occurred.

Conference Call

Athersys, Inc. will host a conference call today at 4:30 PM (Eastern Time) to review the top-line data results of the phase I clinical trial of MultiStem, its cell therapy treatment for individuals following AMI (or heart attack).

Investors and other interested part
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
3. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
4. Angiotech Pharmaceuticals Announces Conference Call and Webcast
5. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
6. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
7. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
8. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
9. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
10. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
11. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global and Chinese Stem Cell Industry Report, 2014-2017" ... are undifferentiated biological cells that can differentiate into specialized ... stem cells. Stem cell therapy can be applied to ... system disease), nervous system diseases, damage or lesion of ...
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market ... their offering. The global companion diagnostics ... 22.7% from 2014 to 2019. Factors such as rising ... of companion diagnostics by the pharmaceutical industry, support from ...
(Date:9/18/2014)...  MEI Pharma, Inc. (Nasdaq: MEIP ), an ... for cancer, announced today that Daniel P. Gold , ... NewsMakers in the Biotech Industry conference on Friday, ... Millennium Broadway Hotel & Conference Center in New ... be accessed at www.meipharma.com . A replay will be ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3
... half of Americans living with colorectal cancer will ... course of their disease. Radiofrequency ablation, a minimally ... tumor causing cancer cell death with minimal associated ... prolongation of their life by nearly three years, ...
... a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results for the year ended 2009 will be released on Tuesday, March 23, 2010 ... , ... ... ...
... , March 16, 2010 Elbit Imaging,(NASDAQ: EMITF ) ("Elbit Imaging" "Company") announced today that its,wholly-owned subsidiary, Elbit Medical Ltd., ... the Tel Aviv,Stock Exchange. , ... , ... ...
Cached Biology Technology:Living longer: Colon cancer patients gain time with radiofrequency ablation treatment 2Living longer: Colon cancer patients gain time with radiofrequency ablation treatment 3PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 2PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 3Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 2Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 3Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 4Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 5Elbit Imaging Announces Filing of Draft Prospectus for its Subsidiary Elbit Medical Ltd. for Float on Tel Aviv Stock Exchange 6
(Date:9/18/2014)... ever starts a "frequent flyers" program, fruit flies surely ... laboratory has hosted increasing numbers of fruit fly research ... station in April, and another is scheduled launch to ... to launch in December. , Fruit flies are biomedical ... in space. Model organisms can reveal the basis for ...
(Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
(Date:9/18/2014)... tropical rabbitfish which have devastated algal forests in the ... entire Mediterranean basin if their distribution continues to expand ... study, by an international team of researchers led by ... Tomas of the Mediterranean Institute for Advanced Studies in ... ., Members of the team surveyed more than 1000 ...
Breaking Biology News(10 mins):Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Tropical fish a threat to Mediterranean Sea ecosystems 2
... metal scaffolds inserted into blood vessels, to better deliver ... the risk of inflammation that often negates initial benefits. ... an extremely thin layer to bare metal surfaces, may ... make use of metallic implants. , Cardiologists frequently treat ...
... history's worst infectious diseases, but there are many more diseases ... society needs to confront to unlock the future promise of ... focus of a new report by the American Academy of ... been profound. Many diseases that formerly raged unchecked are ...
... flow of carbon through soil is ten times greater than the ... but until now how this happens was at best poorly understood. ... carbon. Now researchers at the University of Warwick have been able ... class of insects to expose the key underground carbon traffic system ...
Cached Biology News:Bare metal stents deliver gene therapy to heart vessels with less inflammation in animal studies 2Report focuses on challenges to unlocking future promise of vaccines 2Bugs expose underground carbon traffic system 10 times more important than fossil fuel burning 2
OmniSlide thermal Cycler for slide applications. 20 slide capacity. Humidity Chamber. Slide Rack can be transferred directly to Wash Module to avoid handling individual slides....
HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
HyPro 20 system for slide hybridization. 20 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
Biology Products: